INSILICO (03696.HK): Chairman increases shareholding by 113,500 shares, votable interest rises to approximately 8.02% ### Body NewTimeSpace News: On 14 September 2026, InSilico Medicine Cayman TopCo (stock code: 03696) issued a voluntary announcement dis
- The share purchase was conducted in compliance with the notification and approval procedures under the Listing Rules, and Mr. Zavoronkovs intends to further acquire shares subject to prevailing market conditions and his investment plans.
- The Company confirmed in the announcement that it has maintained a sufficient public float of its issued shares as required under the Listing Rules following the share purchase.
- The announcement referred to the Company's announcement dated 4 September 2026, on which date the shareholding increase plan was announced.
NewTimeSpace News: On 14 September 2026, InSilico Medicine Cayman TopCo (stock code: 03696) issued a voluntary announcement disclosing that it had received notification from Mr. Zavoronkovs, chairman of the Board, executive director, chief executive officer, chief business officer and single largest shareholder of the Company, that during the period from 4 September 2026 to 7 September 2026 he had used his personal funds to acquire a total of 113,500 ordinary shares of the Company in on-market transactions. Immediately following the share purchase, Mr. Zavoronkovs is entitled to exercise the voting rights attached to 46,757,000 shares, representing approximately 8.02% of the total issued share capital of the Company.
The announcement stated that the share purchase was the first tranche of purchases under the shareholding increase plan announced by Mr. Zavoronkovs on 4 September 2026 and was conducted in compliance with the notification and approval procedures under the Rules Governing the Listing of Securities on the Stock Exchange. Mr. Zavoronkovs intends to further acquire shares, subject to, among other things, prevailing market conditions and his investment plans. The Board considers that Mr. Zavoronkovs' voluntary acquisition of shares through on-market purchases demonstrates his confidence in the long-term development and prospects of the Group.
The Company also confirmed that, based on the information currently available to it and to the best of the directors' knowledge and belief after making all reasonable enquiries, it has maintained a sufficient public float of its issued shares as required under the Listing Rules following the share purchase. As at the date of the announcement, the Board comprised executive directors Dr. Aleksandrs Zavoronkovs and Dr. Ren Feng, non-executive director Dr. Liang Chuanxin, and independent non-executive directors Dr. Wang Jinsong, Dr. Denitsa Milanova and Mr. Roman Kyrychynskyi.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- INSILICO (03696.HK): AI-Driven Candidate Rentosertib Completes First Patient Dosing in Phase III IPF Trial
- INSILICO (03696.HK): Chairman launches share purchase plan in September, up to HKD 16 million
- INSILICO (03696.HK): considering participation in RMB 1.01 billion investment fund focusing on biopharma
- InSilico Medicine (03696.HK): NLRP3 Inhibitor ISM8969/HT-001 Co-Developed with Hengtai Bio Receives NMPA IND Approval for Parkinson's Disease
- Empowered by HKIC's Patient Capital, Insilico Medicine (3696.HK) Enters $600 Million Global Strategic Partnership with Takeda
